NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Monday. The medical device company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.48 by $0.04, Bloomberg Earnings reports. The business had revenue of $247.40 million for the quarter, compared to analyst estimates of $255.70 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The company’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 earnings per share.

Shares of NuVasive (NASDAQ NUVA) traded down 0.69% during trading on Tuesday, hitting $54.59. 2,074,046 shares of the company’s stock were exchanged. NuVasive has a 1-year low of $49.25 and a 1-year high of $81.68. The firm has a market capitalization of $2.77 billion, a PE ratio of 85.97 and a beta of 1.04. The stock’s 50 day moving average is $55.77 and its 200 day moving average is $68.32.

Several analysts have recently commented on the stock. Barclays PLC lowered their price target on shares of NuVasive from $80.00 to $65.00 and set an “overweight” rating on the stock in a research report on Thursday, October 19th. TheStreet lowered shares of NuVasive from a “b-” rating to a “c+” rating in a research report on Friday, October 13th. Robert W. Baird set a $60.00 price target on shares of NuVasive and gave the company a “hold” rating in a research report on Thursday, October 12th. Cowen and Company set a $72.00 price target on shares of NuVasive and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $69.00 price target (down from $74.00) on shares of NuVasive in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $74.62.

WARNING: “NuVasive, Inc. (NUVA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/24/nuvasive-inc-nuva-releases-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

In other NuVasive news, EVP Peter Michael Leddy bought 7,850 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was bought at an average cost of $63.88 per share, with a total value of $501,458.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Gregory T. Lucier bought 2,000 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was acquired at an average cost of $61.52 per share, with a total value of $123,040.00. The disclosure for this purchase can be found here. Insiders acquired 14,850 shares of company stock valued at $955,598 over the last three months. Insiders own 1.20% of the company’s stock.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Earnings History for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.